WO2015004634A3 - Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain - Google Patents

Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain Download PDF

Info

Publication number
WO2015004634A3
WO2015004634A3 PCT/IB2014/063019 IB2014063019W WO2015004634A3 WO 2015004634 A3 WO2015004634 A3 WO 2015004634A3 IB 2014063019 W IB2014063019 W IB 2014063019W WO 2015004634 A3 WO2015004634 A3 WO 2015004634A3
Authority
WO
WIPO (PCT)
Prior art keywords
paracetamol
celecoxib
treatment
inflammatory pain
synergistic combination
Prior art date
Application number
PCT/IB2014/063019
Other languages
Spanish (es)
French (fr)
Other versions
WO2015004634A2 (en
Inventor
Jorge Fernando CANTÚ MEDELLIN
Original Assignee
More Pharma Corporation, S. De R.L. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015004634(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corporation, S. De R.L. De C.V. filed Critical More Pharma Corporation, S. De R.L. De C.V.
Priority to MX2015013911A priority Critical patent/MX366118B/en
Priority to CU2016000002A priority patent/CU24440B1/en
Publication of WO2015004634A2 publication Critical patent/WO2015004634A2/en
Publication of WO2015004634A3 publication Critical patent/WO2015004634A3/en
Priority to CR20160021A priority patent/CR20160021A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a combination of paracetamol and celecoxib, which, in specific quantities, generate potentiation of analgesic effect against inflammatory-type pain. Specifically, the invention relates to a synergistic combination of between 375 and 500 mg of paracetamol and between 50 and 100 mg of celecoxib, which can be used for the treatment of inflammatory pain in animals and humans, as well as to the use of said active principles in the quantities indicated in the production of synergistic pharmaceutical compositions.
PCT/IB2014/063019 2013-07-11 2014-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain WO2015004634A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2015013911A MX366118B (en) 2013-07-11 2014-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain.
CU2016000002A CU24440B1 (en) 2013-07-11 2014-07-11 PHARMACEUTICAL COMPOSITION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN
CR20160021A CR20160021A (en) 2013-07-11 2016-01-11 PARACETAMOL / CELECOXIB SYNERGISTIC COMBINATION FOR THE INFLAMMATORY PAIN TREATMENT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (en) 2013-07-11 2013-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain
IBPCT/IB2013/055710 2013-07-11

Publications (2)

Publication Number Publication Date
WO2015004634A2 WO2015004634A2 (en) 2015-01-15
WO2015004634A3 true WO2015004634A3 (en) 2015-04-09

Family

ID=52279400

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2013/055710 WO2015004505A1 (en) 2013-07-11 2013-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain
PCT/IB2014/063019 WO2015004634A2 (en) 2013-07-11 2014-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/055710 WO2015004505A1 (en) 2013-07-11 2013-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain

Country Status (8)

Country Link
CL (1) CL2015003211A1 (en)
CR (1) CR20160021A (en)
CU (1) CU24440B1 (en)
DO (1) DOP2016000008A (en)
EC (1) ECSP16005679A (en)
MX (1) MX366118B (en)
PE (2) PE20160239A1 (en)
WO (2) WO2015004505A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090517A1 (en) * 2002-02-19 2005-04-28 Norris Michael C. Pharmaceutical combinations of cox-2 inhibitors and opiates
WO2006043025A1 (en) * 2004-10-19 2006-04-27 Reckitt Benckiser Healthcare (Uk) Limited Granular compositions comprising solidified melt granules of a cox-2 selective inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090517A1 (en) * 2002-02-19 2005-04-28 Norris Michael C. Pharmaceutical combinations of cox-2 inhibitors and opiates
WO2006043025A1 (en) * 2004-10-19 2006-04-27 Reckitt Benckiser Healthcare (Uk) Limited Granular compositions comprising solidified melt granules of a cox-2 selective inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATZ W A ET AL.: "Dilemmas in Chronic/Persistent Pain Management.", DISEASE-A-MONTH, vol. 56, no. 4, CHICAGO, IL , US, pages 233 - 250, XP026985412 *

Also Published As

Publication number Publication date
PE20160239A1 (en) 2016-05-13
CR20160021A (en) 2016-04-08
DOP2016000008A (en) 2016-03-15
MX366118B (en) 2019-06-27
CU20160002A7 (en) 2016-06-29
WO2015004505A1 (en) 2015-01-15
MX2015013911A (en) 2015-12-08
CU24440B1 (en) 2019-09-04
CL2015003211A1 (en) 2016-04-29
WO2015004634A2 (en) 2015-01-15
PE20170305A1 (en) 2017-04-21
ECSP16005679A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2015004644A (en) Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2015009105A (en) Solid solution compositions and use in chronic inflammation.
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX2015009058A (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
MX365427B (en) Transdermal compositions of ibuprofen and methods of use thereof.
MX2015009045A (en) Compositions and methods for treating severe pain.
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2014153009A3 (en) Thiosaccharide mucolytic agents
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2016000294A (en) Pharmaceutical composition for a sustained release of lanreotide.
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
WO2015082590A3 (en) Bis-mmf derivatives
WO2015004634A3 (en) Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
MA39009A (en) Compositions pharmaceutiques comprenant un agent actif
IN2013MU03428A (en)
MX2018004532A (en) Combination of trazodone and gabapentin for the treatment of pain.
AU2014353885A8 (en) Prevention and treatment of toxicosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14822222

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/013911

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015029461

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 000043-2016

Country of ref document: PE

Ref document number: CR2016-000021

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 16005863

Country of ref document: CO

122 Ep: pct application non-entry in european phase

Ref document number: 14822222

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 002763-2016

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 112015029461

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151125